Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026
Laiba Immad
Thu, February 19, 2026 at 11:00 AM GMT+9 2 min read
In this article:
TEVA
-0.87%
TEVJF
+30.47%
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds.
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is given the second position on our list.
TheFly reported on February 9 that Goldman Sachs raised its price target on TEVA to $45 from $36, and gave it a Buy rating. The company’s enhanced business profile is reflected in the upgrade, which has been reinforced by advancements made throughout its branded portfolio and the elimination of prior overhangs. The firm sees the present level as justified, given TEVA’s potential for above-consensus, double-digit earnings growth driven by sales increase, margin improvement, and decreased debt, even though the stock now trades above historical valuation multiples.
Additionally, on January 28, Teva Pharmaceutical Industries Limited (NYSE:TEVA) said that, despite Revlimid being a $1.1 billion barrier, it anticipates making $16.4 to $16.4 billion in sales in 2026. Among TEVA’s long-term goals are a non-GAAP operating margin of 30% by 2027 and a mid-single-digit compound annual growth rate (CAGR) in revenue through 2030. A pipeline full of milestones that position the company for consistent, long-term growth, ongoing enhancements to the balance sheet, and developments in its main growth products—AJOVY, UZEDY, and AUSTEDO—all help to achieve these objectives.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a global pharmaceutical company specializing in generic and specialty medicines. It develops, manufactures, and markets treatments across multiple therapeutic areas, aiming to improve patient access to high-quality, affordable healthcare worldwide.
While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
****READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts ****and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.
Disclosure: None.
Terms and Privacy Policy
Privacy Dashboard
More Info